Scholarlink

<p>Loss-of-function (LOF) alterations in <i>PTCH1</i> are a hallmark of basal cell carcinoma (BCC) and drive activation of the Hedgehog (Hh) signaling pathway. Hh inhibitors are approved to treat advanced BCC, but little is known about the frequency, biology, and treatment of <i>PTCH1</i> alterations in other cancers. We analyzed <i>PTCH1</i> LOF alterations across diverse solid tumors and evaluated outcomes of patients with non-BCC tumors who received Hh inhibitors. Among 121,490 tumor samples, 2064 (1.7%) harbored <i>PTCH1</i> LOF alterations. Among 13 patients with non-BCC tumors treated with an Hh inhibitor, the response rate was 31%, with responses seen in sebaceous adenocarcinoma, squamous cell lung cancer (SCC), cutaneous SCC and glioblastoma. Median progression-free survival was 4.1 months, and median overall survival was 9.8 months. <i>PTCH1</i> LOF alterations may identify a tumor-agnostic subset of patients who could derive benefit from Hh inhibitors beyond BCC, supporting further prospective evaluation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

PTCH1 mutations and tumor-agnostic clinical outcomes with hedgehog pathway inhibitors across cancer types

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月17日

查看全文
  • Antoine Desilets,
  • Matteo Repetto,
  • Soo Ryum Yang,
  • Monica F. Chen,
  • Bryan Novak,
  • Emiliano Cocco,
  • Cristal Velilla,
  • Yelena Kemel,
  • Pier Selenica,
  • Allison Richards,
  • Mark T. A. Donoghue,
  • Dazhi Liu,
  • Ezra Rosen,
  • Aliya Khurram,
  • Britta Weigelt,
  • Bob T. Li,
  • Rona Yaeger,
  • Marc Ladanyi,
  • Chaitanya Bandlamudi,
  • Ying L. Liu,
  • Maria I. Carlo,
  • Lauren G. Banaszak,
  • Alicia Latham,
  • Zsofia K. Stadler,
  • Kenneth Offit,
  • Diana Mandelker,
  • Alan L. Ho,
  • Alexander Drilon,
  • Yonina R. Murciano-Goroff

摘要

Loss-of-function (LOF) alterations in PTCH1 are a hallmark of basal cell carcinoma (BCC) and drive activation of the Hedgehog (Hh) signaling pathway. Hh inhibitors are approved to treat advanced BCC, but little is known about the frequency, biology, and treatment of PTCH1 alterations in other cancers. We analyzed PTCH1 LOF alterations across diverse solid tumors and evaluated outcomes of patients with non-BCC tumors who received Hh inhibitors. Among 121,490 tumor samples, 2064 (1.7%) harbored PTCH1 LOF alterations. Among 13 patients with non-BCC tumors treated with an Hh inhibitor, the response rate was 31%, with responses seen in sebaceous adenocarcinoma, squamous cell lung cancer (SCC), cutaneous SCC and glioblastoma. Median progression-free survival was 4.1 months, and median overall survival was 9.8 months. PTCH1 LOF alterations may identify a tumor-agnostic subset of patients who could derive benefit from Hh inhibitors beyond BCC, supporting further prospective evaluation.